Clinical Trial: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults
Study Status: Completed
Recruit Status: RECRUITING
Condition: Malaria
Study Type: INTERVENTIONAL
Official Title: A Phase 1, Dose Escalation, Double Blind, Placebo Controlled Clinical Trial With Controlled Human Malaria Infections (CHMI) to Evaluate Safety, Tolerability, Pharmacokinetics, and Protective Efficacy
Brief Summary:
This is a First-in-Human (FiH) double-blind, randomized, placebo-controlled, two-part, dose-escalation trial of MAM01 monoclonal antibody (mAb) targeting the Plasmodium falciparum (Pf) Circumsporozoite Protein (CSP).This study will evaluate the safety, tolerability, pharmacokinetics (PK), and protective efficacy of MAM01, as well as safety and PK of repeat subcutaneous (SC) dosing.
Read more